Evidence map›Paper›PMID 40055232›Full record

ArticleEuropean radiology2025

Diagnostic performance of contrast-enhanced US in small liver nodules not conclusively characterized after MRI in cirrhotic patients.

Belén Saborido, Anna Darnell, Alejandro Forner, Ángeles García-Criado, Alba Díaz, Carmen Ayuso, Ramon Vilana, Jordi Bruix, María Reig, Jordi Rimola

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Early screening for liver cancer must be performed.World journal of hepatology · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Belén SaboridoBCLC Group, Radiology Department, Hospital Clínic de Barcelona, Barcelona, Spain.
Anna DarnellBCLC Group, Radiology Department, Hospital Clínic de Barcelona, Barcelona, Spain.
Alejandro FornerBCLC Group, Liver Unit, Hospital Clínic de Barcelona, Barcelona, Spain.
Ángeles García-CriadoBCLC Group, Radiology Department, Hospital Clínic de Barcelona, Barcelona, Spain.
Alba DíazIDIBAPS, Barcelona, Spain.
Carmen AyusoBCLC Group, Radiology Department, Hospital Clínic de Barcelona, Barcelona, Spain.
Ramon VilanaBCLC Group, Radiology Department, Hospital Clínic de Barcelona, Barcelona, Spain.
Jordi BruixIDIBAPS, Barcelona, Spain.
María ReigBCLC Group, Liver Unit, Hospital Clínic de Barcelona, Barcelona, Spain.
Jordi RimolaBCLC Group, Radiology Department, Hospital Clínic de Barcelona, Barcelona, Spain. jrimola@clinic.cat.ORCID http://orcid.org/0000-0002-1814-4198

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIn patients at risk of hepatocellular carcinoma (HCC), new focal liver lesions identified at ultrasound screening require further characterization by CT or MRI. If these techniques cannot conclusively characterize a lesion, a biopsy or an alternative imaging modality such as contrast-enhanced ultrasound (CEUS) is considered. We aimed to determine the diagnostic yield of CEUS in a sequential noninvasive diagnostic strategy for solitary nodules ≤ 20 mm detected in cirrhotic patients during US surveillance characterized as inconclusive on MRI.

methodsPost hoc analysis of a single-center prospective cohort of high-risk patients (Child A or B) with no prior history of HCC and new liver nodules (≤ 20 mm) detected on screening US who underwent CEUS after inconclusive MRI (LI-RADS-2, LI-RADS-3, LI-RADS-4, or LI-RADS-M) between January 2006 and February 2017. We compared the characterization of nodules by LI-RADS v.2018 alone vs characterization after considering subsequent CEUS-LR v.2017 against the final diagnosis by biopsy or follow-up.

resultsOf the 75 nodules included, CEUS upgraded 45 (63.4%); of these, 13 nodules classified as LR3 or LR4 at MRI were classified as CEUS-LR5. Altogether, 15 (21.1%) nodules inconclusive on MRI were classified as CEUS-LR5. CEUS yielded 37.5% (95% CI: 22.73‒54.20%) sensitivity and 100% specificity (95% CI: 88.78-100%) for HCC.

conclusionAdding CEUS to the workup of liver nodules with inconclusive MRI findings demonstrated high specificity for HCC, particularly benefiting nodules categorized as LR3 at MRI. KEY POINTS: Question MRI's limited sensitivity in diagnosing small HCCs in cirrhotic patients results in inconclusive classification of a high proportion of screening-detected lesions. Findings Adding CEUS to the work-up for inconclusive liver nodules at MRI yielded 100% specificity (95% CI: 88.78-100%) and 37.5% (95% CI: 22.73-54.20%) sensitivity for the HCC diagnosis. Clinical relevance CEUS is a valuable problem-solving tool in the work-up of small liver nodules with inconclusive MRI findings in cirrhotic patients.

Indexed as

Carcinoma, HepatocellularContrast MediaLiver CirrhosisLiver NeoplasmsMagnetic Resonance ImagingAdultAgedFemaleHumansMaleMiddle AgedProspective StudiesSensitivity and SpecificityUltrasonographyContrast MediaCirrhosisContrast-enhanced ultrasoundHepatocellular carcinomaLiverMagnetic resonance

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.